“Our findings demonstrate that KCL-286 not only targets DNA damage but also reduces inflammation, two processes that occur very early in Alzheimer's disease progression. This highlights its potential as a disease-modifying therapy rather than simply addressing symptoms,”

Maria Goncalves · said date not stated · reported 2026-11-03

Dr. Goncalves said KCL-286 targets both DNA damage and inflammation, which occur early in Alzheimer's disease progression.